What is the recommended dosing regimen of 20% mannitol (200 mg/mL) for an adult with acute subdural hematoma, including initial dose, repeat dosing interval, maximum daily dose, and monitoring parameters?

Mannitol Dosing for Acute Subdural Hematoma

For an adult with acute subdural hematoma showing signs of elevated intracranial pressure or impending herniation, administer mannitol 20% at 0.25–0.5 g/kg IV over 20 minutes, repeated every 6 hours as needed, with a maximum daily dose of 2 g/kg. 1

Initial Dose and Administration

• Standard initial dose: 0.25–0.5 g/kg IV (approximately 250 mOsm) infused over 20 minutes 1, 2
• For acute intracranial hypertensive crisis with signs of imminent herniation (dilated pupils, Cushing's triad, acute deterioration), use the higher dose of 0.5–1 g/kg IV over 15 minutes 1, 2
• The 0.25 g/kg dose is as effective as higher doses for acute ICP reduction while minimizing osmotic complications 2

Pre-Administration Requirements

• Insert a Foley catheter before infusion to manage the profound osmotic diuresis that follows 1, 2
• Use an in-line filter and ensure the solution is clear; do not use solutions containing crystals 1, 2
• Elevate the head of bed to 20–30° with head in neutral position 1

Repeat Dosing Interval

• Repeat every 6 hours as needed based on clinical signs of elevated ICP 1, 2
• Mannitol's maximal effect occurs 10–15 minutes after administration, with duration of action lasting 2–4 hours 1, 3
• Administer only when there are clear neurological signs of elevated ICP—such as pupillary abnormalities, declining level of consciousness, or acute neurological deterioration 1, 3

Maximum Daily Dose

• Maximum total daily dose: 2 g/kg 1, 2
• This limit prevents excessive cumulative dosing that allows mannitol to cross into brain parenchyma, increasing risk of rebound intracranial hypertension 1

Critical Monitoring Parameters

Serum Osmolality (Most Important)

• Measure serum osmolality every 6 hours during active therapy 1
• Discontinue mannitol when serum osmolality exceeds 320 mOsm/L to prevent renal failure 1, 2, 4
• Serum osmolality increases of ≥10 mOsm are associated with effective ICP reduction 1

Electrolytes and Fluid Balance

• Check electrolytes (sodium, potassium, chloride) every 6 hours during active mannitol therapy 1
• Monitor fluid balance closely; mannitol causes osmotic diuresis requiring volume compensation with crystalloid solutions 1, 3
• Avoid hypoosmolar IV fluids (such as 5% dextrose in water); use isotonic or hypertonic maintenance fluids 1

Hemodynamic Parameters

• Maintain cerebral perfusion pressure (CPP) at 60–70 mmHg throughout treatment 1, 2, 3
• Monitor blood pressure continuously; mannitol can cause hypovolemia and hypotension due to its potent diuretic effect 1

Important Clinical Caveats

Absolute Contraindications

• Do not administer mannitol in hypotensive patients with active hemorrhage; bleeding must be controlled first 1
• In hypotensive or hypovolemic patients, hypertonic saline is the superior choice over mannitol 1, 3

Rebound Intracranial Hypertension

• Risk increases with prolonged use or rapid discontinuation, particularly when serum osmolality rises excessively 1, 2
• When discontinuing after prolonged use, gradually extend dosing intervals (e.g., from every 6 hours to every 8 hours, then every 12 hours) rather than stopping abruptly 1

Adjunctive Measures

Mannitol should be used alongside other ICP control measures: 1, 2

• Controlled hyperventilation (target PaCO₂ 34–38 mmHg, avoid <30 mmHg)
• Sedation and analgesia
• Head-of-bed elevation to 20–30°
• Cerebrospinal fluid drainage via ventriculostomy if available
• Barbiturate therapy for refractory ICP
• Neuromuscular blockade if needed

Alternative: Hypertonic Saline

• At equiosmotic doses (250 mOsm), mannitol and hypertonic saline have comparable efficacy for ICP reduction 1, 2, 3
• Choose hypertonic saline when hypovolemia, hypotension, or hypernatremia is present 1, 2
• Choose mannitol when hypernatremia exists or improved cerebral blood flow rheology is desired 1, 2
• Mannitol is uniquely associated with improved cerebral oxygenation among ICP-lowering therapies 1, 3

Outcome Expectations

• Despite intensive medical management with mannitol, mortality in patients with increased ICP from subdural hematoma remains high (50–70%) 1
• Mannitol serves as a temporizing measure before definitive treatment such as surgical evacuation or decompressive craniectomy 1
• Neither mannitol nor hypertonic saline has been shown to improve long-term neurological outcomes or survival, despite effectiveness in reducing ICP 1